A heads up to any of our team members who may be in ADMA Biologics (Nasdaq: ADMA). Today, after the market closed the ADMA’s stock, was halted pending news. I assume the news is regarding the approval of BIVIGAM’s prior approval supplement (PAS).
The last update we had was on January 7th when the company responded to a CRL. In the press release, ADMA stated it would be in communications with the FDA to resolve any concerns. This was reiterated in the latest earnings report “ongoing communications with the FDA to obtain approval of the BIVIGAM® drug substance Prior Approval Supplement (“PAS”) required to relaunch the product“.
I am excited about the news. This was what I have been waiting for and as many of you know was a core part of my investment thesis. Regardless of the outcome, it is important to be up and ready for what comes next tomorrow morning. Good luck to everyone and let’s get this bread!
I am/we are long ADMA.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.